MAOB and Alzheimer disease: MAOIs would attenuate the effects of increased MAO-B, although they have not been utilized extensively in treatment of AD; such studies have been conducted mainly with irreversible MAO-B inhibitors such as selegiline and rasagiline, and the results in long-term studies have been generally disappointing (Park et al., 2019; Schneider et al. 2014; Tabi et al. 2020).